Optimal Design of PDX to Study Cancer Pathogenesis and Responses to Therapy

April 9, 2020

During this presentation, Dr. Bankert discusses the optimal design of patient derived xenografts (PDX) to study cancer pathogenesis and responses to therapy.

Optimal Design of PDX to Study Cancer Pathogenesis and Responses to Therapy

How-to Guide for Selecting Xenografts & Mouse Models for Preclinical Cancer Research

What Do Experimental Mice Really Cost?

Comparing Immune-Humanized Mouse Platforms for Preclinical Applications

Using Cre-lox Technology in Mouse Modeling

Designing Reproducible Preclinical Research Studies

Comparing Immunodeficient Models for Cancer, Immunity, and Transplant Research

The Consequences of Sex Bias in Preclinical Research

Translatable Efficacy & Safety Testing of mAb, Bispecific, & CAR T Therapies

Key Considerations to Optimize Preclinical Aging Studies

De-Risk Therapeutic Antibody Drug Development Using Humanized FcRn Platforms (Oct. 24, 2023)

New Immune-humanized Models Support More Diverse Human Immune Cell Lineages

Rapid In Vivo Evaluation of Immuno-Modulatory Therapies Using Hu-PBMC NSG™ Mice

Comparing Mouse Models for Obesity and Diabetes Research

The Many Faces of C57BL/6 Mice: Research Impact of B6 Substrain Differences

Essential Tips for Choosing and Using Mouse Models in Research

In Vivo Platforms for Autoimmune Pharmacology: MS-EAE Capabilities

Support the 3 R’s with Effective Mouse Colony Management Practices

Preclinical Assessment of Investigational Gene Therapy Products for Neuroscience

In Vivo Drug Discovery Platforms for Amyotrophic Lateral Sclerosis

Onco-Hu® Mouse Models